LAPROPHAN

Laprophan is a leading international pharmaceutical company, with a commitment to innovation, quality, and patient-centric care for over 70 years. The company's manufacturing facility and distribution center, located in Casablanca, spans 23,000 sqm and 13,000 sqm respectively, equipped with state-of-the-art technology and machinery to ensure the highest standards of quality and safety.

The company offers a diverse and extensive product portfolio, including over 160 forms of pharmaceutical products, 70 of which are manufactured under its own brands, and more than 400 specialties covering a wide range of therapeutic classes. Their dedication to researching, developing, and bringing new, innovative products to the market reflects their commitment to patient-centric care and improving the lives of patients worldwide.

Laprophan, founded in 1949 and headquartered in Morocco, recently secured a MAD750.00M Venture Round investment on 21st February 2023, with DEG, FMO, Proparco, Mediterrania Capital Partners as the investors. The company's impressive legacy, strong market position, and commitment to innovation make it an attractive prospect for potential investors seeking opportunities in the pharmaceutical industry.